Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher

Stock Information for Rocket Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Rocket Pharmaceuticals Inc.

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference
Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
ROCKET ALERT: Bragar Eagel & Squire, P.C. is Investigating Rocket Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI(TM) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.